Metagenomi, Inc.

NasdaqGS:MGX Stock Report

Market Cap: US$71.5m

Metagenomi Management

Management criteria checks 1/4

Metagenomi's CEO is Brian Thomas, appointed in Sep 2016, has a tenure of 8.5 years. total yearly compensation is $7.83M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 6.35% of the company’s shares, worth $4.54M. The average tenure of the management team and the board of directors is 2.2 years and 2.3 years respectively.

Key information

Brian Thomas

Chief executive officer

US$7.8m

Total compensation

CEO salary percentage6.6%
CEO tenure8.5yrs
CEO ownership6.4%
Management average tenure2.2yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential

Jan 28

The Market Doesn't Like What It Sees From Metagenomi, Inc.'s (NASDAQ:MGX) Revenues Yet As Shares Tumble 26%

Jan 28
The Market Doesn't Like What It Sees From Metagenomi, Inc.'s (NASDAQ:MGX) Revenues Yet As Shares Tumble 26%

We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully

Jan 14
We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully

Metagenomi, Inc. (NASDAQ:MGX) Stock Catapults 106% Though Its Price And Business Still Lag The Industry

Dec 10
Metagenomi, Inc. (NASDAQ:MGX) Stock Catapults 106% Though Its Price And Business Still Lag The Industry

CEO Compensation Analysis

How has Brian Thomas's remuneration changed compared to Metagenomi's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$74m

Jun 30 2024n/an/a

-US$75m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$8mUS$517k

-US$68m

Sep 30 2023n/an/a

-US$64m

Jun 30 2023n/an/a

-US$54m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$2mUS$500k

-US$44m

Compensation vs Market: Brian's total compensation ($USD7.83M) is above average for companies of similar size in the US market ($USD641.60K).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.

CEO

Brian Thomas (55 yo)

8.5yrs

Tenure

US$7,825,855

Compensation

Dr. Brian Charles Thomas, Ph. D., is a Co-Founder of Metagenomi, Inc. (Fomerly, Metagenomi Technologies, LLC). He serves as Chairman of the Board of Metagenomi, Inc. since February 2024. He serves as Chief...

Leadership Team

NamePositionTenureCompensationOwnership
Brian Thomas
Co-Founder8.5yrsUS$7.83m6.35%
$ 4.5m
Jian Irish
President4.2yrsUS$2.51m1.56%
$ 1.1m
Sarah Noonberg
Chief Medical Officer2.2yrsUS$2.04m0.11%
$ 81.4k
Joseph Knowles
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Pamela Wapnick
Chief Financial Officer1.3yrsno data0.044%
$ 31.3k
Matthew Wein
Vice President of Corporate Legal1.1yrsno data0.025%
$ 18.1k
Alan Brooks
Senior Vice President of Preclinical2.2yrsno datano data
Christopher Brown
Head of Discoveryno datano datano data

2.2yrs

Average Tenure

56yo

Average Age

Experienced Management: MGX's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Thomas
Co-Founder1.1yrsUS$7.83m6.35%
$ 4.5m
Jian Irish
Presidentno dataUS$2.51m1.56%
$ 1.1m
Joseph Knowles
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Eric Bjerkholt
Directorless than a yearno datano data
Willard Dere
Independent Director3.6yrsUS$49.20k0.14%
$ 97.9k
Philip Greenberg
Member of Scientific Advisory Boardno datano datano data
Chad Cowan
Member of Scientific Advisory Boardno datano datano data
Juergen Eckhardt
Independent Directorno datano datano data
Sebastian Bernales
Independent Director4.3yrsno data2.06%
$ 1.5m
Aude Chapuis
Member of Scientific Advisory Boardno datano datano data
Thomas Schmitt
Member of Scientific Advisory Boardno datano datano data

2.3yrs

Average Tenure

58yo

Average Age

Experienced Board: MGX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/14 23:04
End of Day Share Price 2025/03/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Metagenomi, Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantinos BiliourisBMO Capital Markets Equity Research
Yevgeniya LivshitsChardan Capital Markets, LLC
Mitchell KapoorH.C. Wainwright & Co.